Update on Disease-Modifying/Preventive Therapies in Alzheimer’s Disease
نویسندگان
چکیده
Alzheimer's disease (AD) is increasingly becoming a major health problem throughout the US and Western Europe. As the remnants of the Baby Boom generation begin to reach their seniority at the turn of the twenty-first century, the disease has been unwillingly brought to the attention of the public eye. A disease that has traditionally been associated with an aging population has thus become a heated topic of discussion as modern research attempts to prevent and treat this major health burden and plague of the next decade.
منابع مشابه
The Correlation of Biological Activity and Chemical Structure of Quinolizidinyl Derivatives as Inhibitor of Alzheimer’s Disease with Linear and Non-linear Models
In this research,QSAR study has been carried out on quinolizidinyl derivatives as potent inhibitors of Acetyl and Butyrylcholin esterase in Alzheimer’s disease. Despite significant research efforts in both industry and academia, there are currently no diseases modifying therapies available to treat this illness. Significant evidence suggests that the pathology of AD is linked to generation of β...
متن کاملAn Update of Pharmacological & Non-Pharmacological Therapies for COVID-19 Pandemic Trivia
The whole planet is facing one of the scariest pandemic situations in this era. On 11th February, 2020 the World Health Organization announced the name of an unknown disease as COVID-19, which is caused by the ssRNA virus SARS-CoV-2 (formally recognized as a sister of SARS-CoV and MERS-CoV). The epicenter of this disease is Wuhan, Hubei Province, China. COVID-19 can affect all age groups but pa...
متن کاملThe past, present, and future of disease-modifying therapies for Alzheimer’s disease
The development of disease-modifying therapies for Alzheimer's disease (AD) is an urgent issue. Progress in the understanding of AD pathophysiology based on the amyloid hypothesis has led to the development of numerous candidate disease-modifying therapies over the past 15 years. The therapeutic target, amyloid β (Aβ), starts to accumulate in AD brains long before the onset of cognitive decline...
متن کاملGenetic testing for Alzheimer’s disease risk
Experimental preventive therapies are now entering clinical trials, ushering in a new era of research. For instance, a new Alzheimer’s disease prevention trial [3]—which is slated to begin in late 2015 and jointly run by teams from Novartis and the Banner Alzheimer’s Institute in Phoenix, Arizona—is giving people a reason to consider genetic testing. It has also prompted researchers to think de...
متن کاملHow to Reduce Your Risk of Alzheimer’s Without Taking Drugs
Scientists now know a lot about Alzheimer’s disease, and preventive therapies probably aren’t far off. But even when they become available, such therapies will almost certainly be very expensive. The only products currently being tested in large-scale Alzheimer’s prevention trials are antibodies against the Alzheimer’s-associated amyloid beta (Aβ) protein. Antibodies are large and delicate prot...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 4 شماره
صفحات -
تاریخ انتشار 2015